心脉医疗(688016) - 2024 Q2 - 季度业绩预告

Financial Performance - The company achieved operating revenue of CNY 621.62 million and a net profit attributable to the parent company of CNY 279.53 million for the first half of 2023[4]. - For the first half of 2024, the company expects operating revenue to be between CNY 777.03 million and CNY 808.11 million, representing an increase of CNY 155.41 million to CNY 186.49 million, or a year-on-year growth of 25% to 30%[8]. - The projected net profit attributable to the parent company for the first half of 2024 is expected to be between CNY 391.34 million and CNY 419.29 million, an increase of CNY 111.81 million to CNY 139.76 million, or a year-on-year growth of 40% to 50%[16]. Market Development - The company has seen rapid growth in sales and profit due to innovative products such as the Castor branched aortic stent graft and Minos abdominal aortic stent graft, contributing to increased competitiveness in the aortic and peripheral vascular intervention market[11]. - The company is actively developing the market for municipal and county-level hospitals in China and promoting its products in international markets, including Europe, Latin America, and Asia-Pacific[6].